毒性及对大剂量异环磷酰胺+美司钠作为晚期乳腺癌挽救治疗的反应
Toxicity and response to high-dose ifosfamide + mesna as salvage therapy for advanced breast cancer.
作者信息
Steger G G, Dittrich C, Schlappack O, Mader R, Herold C, Brade W P, Keller A, Moser K
机构信息
Department of Chemotherapy, University of Vienna, Austria.
出版信息
J Cancer Res Clin Oncol. 1988;114(6):602-4. doi: 10.1007/BF00398184.
Abstract
Twenty-six cycles of high-dose ifosfamide + mesna (HD-IFO + M) were applied to seven female patients with advanced breast cancer refractory to prior treatment, using three different durations of continuous infusion (4, 24, and 48 h) every 3 weeks. To evaluate the most tolerable time schedule, the duration of the infusions was changed periodically in each patient. Toxicity was low in general, but continuous infusion of HD-IFO + M over 24 h appeared to be the best tolerated. One partial response lasting 27 weeks was achieved and four patients achieved stable disease lasting from 9 to 12 weeks.
摘要
对7例先前治疗难治的晚期乳腺癌女性患者应用26个周期的大剂量异环磷酰胺+美司钠（HD-IFO+M），每3周采用三种不同的持续输注时间（4、24和48小时）。为评估最耐受的时间安排，在每位患者中定期改变输注持续时间。总体毒性较低，但24小时持续输注HD-IFO+M似乎耐受性最佳。获得1例持续27周的部分缓解，4例患者病情稳定持续9至12周。
相似文献
1
Toxicity and response to high-dose ifosfamide + mesna as salvage therapy for advanced breast cancer.毒性及对大剂量异环磷酰胺+美司钠作为晚期乳腺癌挽救治疗的反应
J Cancer Res Clin Oncol. 1988;114(6):602-4. doi: 10.1007/BF00398184.
2
Dosing and side-effects of ifosfamide plus mesna.异环磷酰胺加美司钠的剂量及副作用
J Cancer Res Clin Oncol. 1991;117 Suppl 4(Suppl 4):S164-86. doi: 10.1007/BF01613224.
3
Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: a phase II study.对无法手术的胰腺癌患者连续5天输注异环磷酰胺并联合美司钠：一项II期研究。
J Cancer Res Clin Oncol. 1991;117 Suppl 4(Suppl 4):S135-8. doi: 10.1007/BF01613218.
4
Ambulatory high-dose 5-day continuous-infusion ifosfamide combination chemotherapy in advanced solid tumors: a feasibility study.门诊大剂量5天持续输注异环磷酰胺联合化疗用于晚期实体瘤：一项可行性研究
J Cancer Res Clin Oncol. 1991;117 Suppl 4:S125-8. doi: 10.1007/BF01613216.
5
High-dose ifosfamide and mesna in advanced breast cancer. A phase II study.高剂量异环磷酰胺与美司钠治疗晚期乳腺癌：一项II期研究
Cancer Chemother Pharmacol. 1990;26 Suppl:S91-2. doi: 10.1007/BF00685432.
6
Clinical Outcome of Neoadjuvant Radiochemotherapy in Locally Advanced Cervical Cancer: Results of an Open Prospective, Multicenter Phase 2 Study of the North-Eastern German Society of Gynecological Oncology.局部晚期宫颈癌新辅助放化疗的临床结局：德国东北部妇科肿瘤学会一项开放前瞻性多中心2期研究的结果
Int J Gynecol Cancer. 2017 Mar;27(3):500-506. doi: 10.1097/IGC.0000000000000894.
7
Ifosfamide treatment as a 10-day continuous intravenous infusion.异环磷酰胺采用为期10天的持续静脉输注治疗。
J Cancer Res Clin Oncol. 1995;121(5):297-302. doi: 10.1007/BF01209597.
8
Experience of the Belgian Society of Medical Oncology with single-administration 5 g/m2 ifosfamide with mesna as second- or third-line therapy in advanced breast cancer.比利时医学肿瘤学会使用单剂量5 g/m²异环磷酰胺加美司钠作为晚期乳腺癌二线或三线治疗的经验。
Cancer Chemother Pharmacol. 1990;26 Suppl:S63-5. doi: 10.1007/BF00685423.
9
6-Day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory malignancies.在晚期难治性恶性肿瘤中，高剂量异环磷酰胺与骨髓生长因子联合进行6天持续输注。
J Cancer Res Clin Oncol. 1997;123(4):227-31. doi: 10.1007/BF01240320.
10
Phase I clinical and pharmacokinetic study of combination chemotherapy with topotecan and ifosfamide in patients with progressive or relapsed solid tumors.拓扑替康与异环磷酰胺联合化疗用于进展期或复发实体瘤患者的I期临床及药代动力学研究
J Cancer Res Clin Oncol. 2002 Jun;128(6):313-8. doi: 10.1007/s00432-002-0337-2. Epub 2002 Apr 24.
引用本文的文献
1
Experience of the Belgian Society of Medical Oncology with single-administration 5 g/m2 ifosfamide with mesna as second- or third-line therapy in advanced breast cancer.比利时医学肿瘤学会使用单剂量5 g/m²异环磷酰胺加美司钠作为晚期乳腺癌二线或三线治疗的经验。
Cancer Chemother Pharmacol. 1990;26 Suppl:S63-5. doi: 10.1007/BF00685423.
本文引用的文献
1
Reporting results of cancer treatment.癌症治疗结果报告。
Cancer. 1981 Jan 1;47(1):207-14. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6.
2
Central nervous side effects following ifosfamide monotherapy of advanced renal carcinoma.异环磷酰胺单药治疗晚期肾癌后的中枢神经系统副作用。
J Cancer Res Clin Oncol. 1981;100(1):113-6. doi: 10.1007/BF00405909.
3
High-dose ifosfamide and mesna as continuous infusion over five days--a phase I/II trial.高剂量异环磷酰胺和美司钠持续输注五天——一项I/II期试验。
Cancer Treat Rev. 1983 Sep;10 Suppl A:167-73. doi: 10.1016/s0305-7372(83)80025-5.
4
Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma.2-巯基乙烷磺酸钠（美司钠）预防晚期癌症患者异环磷酰胺诱导的尿路上皮毒性
Lancet. 1980 Sep 27;2(8196):657-9. doi: 10.1016/s0140-6736(80)92703-8.
5
Phase II clinical trial of isophosphamide (NSC-109724) in patients with advances breast cancer.
Cancer Chemother Rep. 1974 Nov-Dec;58(6):861-5.
6
Unexpected toxicity in patients treated with iphosphamide.接受异环磷酰胺治疗的患者出现意外毒性。
Cancer Res. 1972 May;32(5):921-4.
7
Ifosfamide--pharmacology, safety and therapeutic potential.异环磷酰胺——药理学、安全性及治疗潜力
Cancer Treat Rev. 1985 Mar;12(1):1-47. doi: 10.1016/0305-7372(85)90011-8.
8
Ifosfamide/mesna and hematuria.异环磷酰胺/美司钠与血尿
Cancer Treat Rep. 1987 Nov;71(11):1124-5.
9
Ifosfamide/mesa and encephalopathy.异环磷酰胺/美司钠与脑病
Lancet. 1985 Mar 30;1(8431):752. doi: 10.1016/s0140-6736(85)91288-7.
10
Studies on the clinical pharmacology and toxicology of isophosphamide (NSC-109724).异环磷酰胺（NSC-109724）的临床药理学与毒理学研究。
Cancer Treat Rep. 1976 Apr;60(4):445-9.
Zotero 插件